ZS Pharma, a biotech firm that was launched out of the Tech Fort Worth business incubator, has agreed to be acquired by AstraZeneca Plc for $2.7 billion in cash.
ZS Pharma investors will get $90 per share, London-based AstraZeneca said in a statement. That’s a 42 percent premium to Thursday’s close. The board of San Mateo, California-based ZS Pharma agreed to the transaction.